본문 바로가기
KERD
논문KCI 등재

Risk factors in nonalcoholic fatty liver disease

전대원|Eileen L. Yoon|Eunji Ko
대한간학회 (The korean Association for the Study of the Liver)|2023.02|Clinical and Molecular Hepatology|제29권 제1호|pp. 79-85

2

조회

0

다운로드

9

인용

0

참고문헌

키워드

ObesityDiabetes mellitusSarcopeniatype 2Nonalcoholic fatty liver disease

초록

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a global prevalence estimated at approximately 25%. NAFLD is also the leading cause of liver cirrhosis, hepatocellular carcinoma, and death. Additionally, the risk of cardiovascular disease increases with greater NAFLD severity. The liver- and cardiovascular disease-related mortality incident rate ratios among the NAFLD population were 0.77 and 4.79 per 1,000 person-years, respectively. We intend to discuss the risk factors associated with NAFLD in terms of development and progression. Obesity or higher body mass index is closely associated with NAFLD in a dose-dependent manner, but growing evidence suggests that central obesity plays a more important role in the development of NAFLD. Saturated fat and fructose have been reported to be closely related to NAFLD. Fructose intake promotes lipogenesis and impairs mitochondria fat oxidation. The presence of type 2 diabetes is the most powerful predictive risk factor for hepatic fibrosis in patients with NAFLD. Single nucleotide polymorphism is not only associated with the prevalence of NAFLD but also associated with increased liver disease mortality. Obstructive sleep apnea, intestinal dysbiosis, and sarcopenia are associated with the development of NAFLD.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease, with a global prevalence estimated at approximately 25%. NAFLD is also the leading cause of liver cirrhosis, hepatocellular carcinoma, and death. Additionally, the risk of cardiovascular disease increases with greater NAFLD severity. The liver- and cardiovascular disease-related mortality incident rate ratios among the NAFLD population were 0.77 and 4.79 per 1,000 person-years, respectively. We intend to discuss the risk factors associated with NAFLD in terms of development and progression. Obesity or higher body mass index is closely associated with NAFLD in a dose-dependent manner, but growing evidence suggests that central obesity plays a more important role in the development of NAFLD. Saturated fat and fructose have been reported to be closely related to NAFLD. Fructose intake promotes lipogenesis and impairs mitochondria fat oxidation. The presence of type 2 diabetes is the most powerful predictive risk factor for hepatic fibrosis in patients with NAFLD. Single nucleotide polymorphism is not only associated with the prevalence of NAFLD but also associated with increased liver disease mortality. Obstructive sleep apnea, intestinal dysbiosis, and sarcopenia are associated with the development of NAFLD.

참고문헌 (50)

  1. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-Metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
  2. Kim M, "Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea", Liver Int, 42, pp.1536~1544 (2022)
  3. Arrese M, "Insights into nonalcoholic fatty-liver disease heterogeneity", Semin Liver Dis, 41, pp.421~434 (2021)
  4. Estes C, "Modelling NAFLD disease burden in four Asian regions-2019-2030", Aliment Pharmacol Ther, 51, pp.801~811 (2020)
  5. Estes C, "Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease", Hepatology, 67, pp.123~133 (2018)
  6. Younossi Z, "Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis", Hepatology, 69, pp.2672~2682 (2019)
  7. Mantovani A, "Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events : an updated systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 6, pp.903~913 (2021)
  8. Targher G, "NAFLD and increased risk of cardiovascular disease : clinical associations, pathophysiological mechanisms and pharmacological implications", Gut, 69, pp.1691~1705 (2020)
  9. Allen AM, "The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity-A longitudinal cohort study", J Hepatol, 71, pp.1229~1236 (2019)
  10. Simon TG, "Mortality in biopsy-confirmed nonalcoholic fatty liver disease : results from a nationwide cohort", Gut, 70, pp.1375~1382 (2021)
  11. Kim GA, "Association between non-alcoholic fatty liver disease and cancer incidence rate", J Hepatol (2017)[DOI]
  12. Mantovani A, "Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers : a meta-analysis of observational cohort studies", Gut, 71, pp.778~788 (2022)
  13. Younossi ZM, "Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices", Aliment Pharmacol Ther, 52, pp.513~526 (2020)
  14. Simon TG, "Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality", J Hepatol, 75, pp.1034~1041 (2021)
  15. Fracanzani AL, "Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity", Clin Gastroenterol Hepatol, 15, pp.1604~1611 (2017)
  16. Pang Q, "Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index", World J Gastroenterol, 21, pp.1650~1662 (2015)
  17. Tsompanaki E, "Systematic review and metaanalysis : The role of diet in the development of nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol (2021)[DOI]
  18. Kwak JH, "Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease : A cross-sectional study", Clin Nutr, 37, pp.1550~1557 (2018)
  19. shimoto T, "Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice", Proc Natl Acad Sci U S A, 109, pp.4320~4325 (2012)
  20. Lanaspa MA, "Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress : Potential role in fructose-dependent and-independent fatty liver", J Biol Chem, 287, pp.40732~40744 (2012)
  21. Rahman K, "Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol", Gastroenterology, 151, pp.733~746 (2016)
  22. Alferink LJ, "Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population : The Rotterdam Study", Gut, 68, pp.1088~1098 (2019)
  23. Younossi ZM, "The global epidemiology of NAFLD and NASH in patients with type 2 diabetes : A systematic review and meta-analysis", J Hepatol, 71, pp.793~801 (2019)
  24. Nobili V, "Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease", J Hepatol, 71, pp.802~810 (2019)
  25. Kang KA, "Prevalence of significant hepatic fibrosis using magnetic resonance elastography in a health check-up clinic population", Aliment Pharmacol Ther, 51, pp.388~396 (2020)
  26. Park H, "Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with nonalcoholic fatty liver disease", Gut, 71, pp.1035~1036 (2022)
  27. Le P, "Population-based trends in prevalence of nonalcoholic fatty liver disease in US adults with type 2 diabetes", Clin Gastroenterol Hepatol, 17, pp.2377~2378 (2019)
  28. Kwok R, "Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements : a prospective cohort study", Gut, 65, pp.1359~1368 (2016)
  29. Dae Won Jun, "An analysis of polygenic risk scores for non-alcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.446~447 (2021), 대한간학회[DOI]
  30. Trépo E, "Update on NAFLD genetics : From new variants to the clinic", J Hepatol, 72, pp.1196~1209 (2020)
  31. Nobili V, "NAFLD in children : New genes, new diagnostic modalities and new drugs", Nat Rev Gastroenterol Hepatol, 16, pp.517~530 (2019)
  32. Ito T, "The epidemiology of NAFLD and lean NAFLD in Japan : A metaanalysis with individual and forecasting analysis, 1995-2040", Hepatol Int, 15, pp.366~379 (2021)
  33. Unalp-Arida A, "Patatin-like phospholipase domaincontaining protein 3 I148M and liver fat and fibrosis scores predict liver disease mortality in the U. S. population", Hepatology, 71, pp.820~834 (2020)
  34. Umbro I, "Association between non-alcoholic fatty liver disease and obstructive sleep apnea", World J Gastroenterol, 26, pp.2669~2681 (2020)
  35. Musso G, "Association of obstructive sleep apnoea with the presence and severity of non-alcoholic fatty liver disease. A systematic review and meta-analysis", Obes Rev, 14, pp.417~431 (2013)
  36. Savransky V, "Chronic intermittent hypoxia predisposes to liver injury", Hepatology, 45, pp.1007~1013 (2007)
  37. Albillos A, "The gut-liver axis in liver disease : Pathophysiological basis for therapy", J Hepatol, 72, pp.558~577 (2020)
  38. Kolodziejczyk AA, "The role of the microbiome in NAFLD and NASH", EMBO Mol Med, 11, pp.e9302~ (2019)
  39. Martinez-Guryn K, "Small intestine microbiota regulate host digestive and absorptive adaptive responses to dietary lipids", Cell Host Microbe, 23, pp.458~469 (2018)
  40. Hong HC, "Relationship between sarcopenia and nonalcoholic fatty liver disease : The Korean Sarcopenic Obesity Study", Hepatology, 59, pp.1772~1778 (2014)
  41. Lee YH, "Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease : Nationwide surveys(KNHANES 2008-2011)", Hepatology, 63, pp.776~786 (2016)
  42. Koo BK, "Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis", J Hepatol, 66, pp.123~131 (2017)
  43. Moon JH, "Non-alcoholic fatty liver disease and sarcopenia additively increase mortality : a Korean nationwide survey", J Cachexia Sarcopenia Muscle, 12, pp.964~972 (2021)
  44. Zambon Azevedo V, "Impact of sarcopenia on the severity of the liver damage in patients with non-alcoholic fatty liver disease", Front Nutr, 8, pp.774030~ (2022)
  45. Zeng X, "Sarcopenia as a prognostic predictor of liver cirrhosis : a multicentre study in China", J Cachexia Sarcopenia Muscle, 12, pp.1948~1958 (2021)
  46. Merz KE, "Role of skeletal muscle in insulin resistance and glucose uptake", Compr Physiol, 10, pp.785~809 (2020)
  47. Li CW, "Pathogenesis of sarcopenia and the relationship with fat mass : descriptive review", J Cachexia Sarcopenia Muscle, 13, pp.781~794 (2022)
  48. Cotter TG, "Nonalcoholic fatty liver disease 2020 : the state of the disease", Gastroenterology, 158, pp.1851~1864 (2020)
  49. Powell EE, "Non-alcoholic fatty liver disease", Lancet, 397, pp.2212~2224 (2021)
  50. Tantai X, "Effect of sarcopenia on survival in patients with cirrhosis : A meta-analysis", J Hepatol, 76, pp.588~599 (2022)

관련 논문AI추천

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver diseaseAijaz Ahmed, Donghee Kim, Peter Konyn대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Non-alcoholic fatty liver disease: Definition and subtypes김문영, 백순구, Seul Ki Han대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Nonalcoholic fatty liver disease and non-liver comorbiditiesMindie H. Nguyen, Richie Manikat대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Global incidence and prevalence of nonalcoholic fatty liver diseaseCheng Han Ng, Daniel Q. Huang, Darren JH Tan, Eunice Tan, Ju Dong Yang, Kai En Chan, Margaret LP Teng, Mark D. Muthiah, Wen Hui Lim대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Comparison between obese and non-obese nonalcoholic fatty liver diseaseWah-Kheong Chan대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Recent Epidemiology of Nonalcoholic Fatty Liver DiseaseAhmed Aijaz, Kim Donghee, Murag Soumya거트앤리버 소화기연관학회협의회 · Gut and Liver2021 · 제15권 제2호

이 간행물의 다른 논문 (46건)

Subclinical versus advanced forms of alcohol-related liver disease: Need for early detectionLuma Melo, David Martí-Aguado, Ramón Bataller, Concepción Gómez-Medinapp. 1-15PrefaceYoon Jun Kimpp. 2-2PrefaceSeung Up Kimpp. 3-3Non-alcoholic fatty liver disease: Definition and subtypesSeul Ki Han, 김문영, 백순구pp. 5-16Management of refractory ascitesFlorence Wongpp. 16-32
원문 보기